Atara Biotherapeutics, Inc. ATRA
6.76 USD +0.42 (+6.55%)
As ofNov 20, 2026, 12:53 PM EST
6.65 Day range 6.65
3.92 52-week range 19.15
- YTD
- -62.66%
- 1 year
- -48.90%
Revenue & Expenses
Revenue Profit Costs
Latest period ending Dec 31, 2025 · select a line to chart its full history
Income statement
| Fiscal year | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| 120.77M | 128.94M | 8.57M | 63.57M | 20.34M | |
| 99.56M | 107.93M | -313.00K | 63.57M | 20.34M | |
| 35.86M | -83.44M | -276.01M | -280.51M | -340.46M | |
| 32.69M | -85.40M | -276.13M | -228.30M | -340.14M | |
| 2.57 | -11.41 | -65.19 | -56.00 | -91.00 |
Balance sheet
| Fiscal year | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| 8.48M | 25.18M | 25.99M | 93.09M | 106.28M | |
| 20.23M | 109.10M | 165.50M | 376.42M | 468.13M | |
| 58.74M | 206.38M | 264.74M | 249.78M | 188.51M | |
| 51.77M | 68.92M | 80.32M | 88.30M | 25.52M | |
| -38.50M | -97.28M | -99.23M | 126.64M | 279.61M |
Cash flow
| Fiscal year | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| -50.94M | -68.72M | -192.98M | -270.43M | -220.52M | |
| 18.15M | 8.62M | 123.87M | 202.96M | 22.26M | |
| 16.10M | 59.28M | 2.01M | 53.08M | 103.94M | |
| 948.00K | -246.00K | -1.20M | 90.57M | -10.58M | |
| -16.69M | -811.00K | -67.10M | -14.39M | -94.32M |
